Several other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a buy rating to a hold rating in a report on Monday, August 28th. Needham & Company LLC reissued a buy rating and issued a $65.00 price target on shares of Aerie Pharmaceuticals in a research report on Sunday, September 17th. Canaccord Genuity reissued a buy rating on shares of Aerie Pharmaceuticals in a research report on Friday, September 22nd. Cowen reaffirmed a buy rating on shares of Aerie Pharmaceuticals in a research report on Thursday, October 5th. Finally, Cantor Fitzgerald reaffirmed a buy rating and set a $62.00 price objective on shares of Aerie Pharmaceuticals in a research report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company. Aerie Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $72.00.
Aerie Pharmaceuticals (NASDAQ AERI) traded up $0.75 during trading hours on Tuesday, hitting $58.80. 191,505 shares of the stock traded hands, compared to its average volume of 344,264. Aerie Pharmaceuticals has a one year low of $37.80 and a one year high of $66.60. The company has a debt-to-equity ratio of 0.78, a quick ratio of 15.24 and a current ratio of 15.24. The company has a market cap of $2,160.00, a price-to-earnings ratio of -17.55 and a beta of 1.11.
WARNING: “Mizuho Reiterates “Buy” Rating for Aerie Pharmaceuticals (NASDAQ:AERI)” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://stocknewstimes.com/2018/01/11/aerie-pharmaceuticals-aeri-receives-buy-rating-from-mizuho.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.